<DOC>
	<DOCNO>NCT00670657</DOCNO>
	<brief_summary>Patients receive 2mg/kg/day IV daily administration AmBisome® 30-60 minute reaction signs/symptoms positive Candida culture</brief_summary>
	<brief_title>CRITIC - Treatment Candidemia Invasive Candidiasis</brief_title>
	<detailed_description>Subjects enrol receive intravenously AmBisome® 2 mg/kg/day maximum 4 week . Treatment discontinue case failure , adverse event preclude treatment success . In case success AmBisome® 2 mg/kg/day administer least 5 day complete resolution clinical finding active infection least 8 day last positive blood culture culture normally sterile site . It recommend declare failure ( therefore change treatment ) give least 5 day antifungal therapy . Failures patient give less 5 day treatment well document ( e.g . persistent positive culture despite catheter removal , clinical deterioration absence explanation fungal infection ) . Follow-up evaluation conduct 2 4 week end AmBisome® therapy . At end treatment ( time point success failure ) patient may shift oral ( intravenous ) antifungal discretion local investigator , complete response achieve , secondary prophylaxis deem necessary .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Patients admit ICU medical reason meet inclusion criterion Males non pregnant female ( woman childbearing potential must negative serum urine pregnancy test baseline ) . Subjects 14 year old old . Subjects least one positive blood culture isolation Candida spp . specimen normally sterile site ( include abdominal catheter ) , draw within 96 hour prior study entry . Subjects clinical evidence infection AT SOME TIME WITHIN 48 HOURS PRIOR TO ENROLLMENT , include AT LEAST ONE following : 1. temperature &gt; 38°C 2 occasion least 4 hour apart one determination great 38.5°C ( internal , oesophagus , tympani bladder level ) . 2. systolic blood pressure &lt; 90 , &gt; 30 mm Hg decrease systolic BP subject 's normal baseline . 3 . Signs inflammation ( swell , heat , erythema , purulent drainage ) site infect Candida Subjects legal representative ( subject sign case able ) must sign write informed consent form . Written informed consent must obtain studyrelated procedure carry . Subjects history allergy intolerance AmBisome® Subjects receive systemic antifungal therapy within 15 day prior inclusion study Any severe cardiovascular disease ( arrhythmias , particular ) may constitute contraindication AmBisome® administration Subjects absolute neutrophil count less 500/mm3 48 hour enrolment study Subjects diagnosis AIDS ( positive HIV serology association either CD4 cell count &lt; 200 cells/mm3or history opportunistic infection /neoplasm ) , aplastic anemia , Chronic Granulomatous Disease . Subjects moderate severe liver disease define one following : * Alkaline phosphatase , ALT , AST , total bilirubin great 5 time ULN ( upper limit normal ) Subjects severe renal impairment define serum creatinine 2.5 mg/dL . Women pregnant breastfeeding . Subjects unlikely survive 24 hour . Subjects previously participate study . Subjects receive within two week study entry , receive likely receive investigational drug ( unlicensed new chemical entity ) .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>candidemia</keyword>
	<keyword>invasive candidiasis</keyword>
	<keyword>Ambisome</keyword>
	<keyword>liposomal amphotericin B</keyword>
</DOC>